# New Combination of Chemoimmunotherapy for Systemic B-cell Lymphoma With Central Nervous System Involvement

> **NCT02329080** · PHASE2 · COMPLETED · sponsor: **International Extranodal Lymphoma Study Group (IELSG)** · enrollment: 79 (actual)

## Conditions studied

- Diffuse Large B-cell Lymphoma

## Interventions

- **DRUG:** Methotrexate
- **DRUG:** Rituximab
- **DRUG:** Cytarabine
- **DRUG:** Thiotepa
- **DRUG:** liposomial cytarabine
- **DRUG:** Etoposide
- **DRUG:** Ifosfamide
- **DRUG:** Carmustine
- **RADIATION:** whole brain radiotherapy

## Key facts

- **NCT ID:** NCT02329080
- **Lead sponsor:** International Extranodal Lymphoma Study Group (IELSG)
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-12
- **Primary completion:** 2019-08
- **Final completion:** 2024-03-22
- **Target enrollment:** 79 (ACTUAL)
- **Last updated:** 2025-07-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02329080

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02329080, "New Combination of Chemoimmunotherapy for Systemic B-cell Lymphoma With Central Nervous System Involvement". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02329080. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*